Three-day icatibant on top of standard care in patients with COVID-19 pneumonia (ICAT·COVID): a randomized, open-label, phase 2, proof-of-concept trial.
Pierre MalchairJordi GiolVanesa GarcíaOrlando RodríguezJosé Carlos RuibalAlvaro ZarauzaFerrán LlopisLeire MatellánTania BernalBeatriz SolísAurema OteroThiago CarnavalHector JofreJavier JacobXavier SolanichArnau AntolíGemma RocamoraSebastián Videlanull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Adding icatibant to standard care was safe and improved both COVID-19 pneumonia and mortality in this proof-of-concept study. A larger, phase 3 trial is warranted to establish the clinical value of this treatment.
Keyphrases
- coronavirus disease
- sars cov
- open label
- healthcare
- palliative care
- clinical trial
- phase iii
- phase ii
- quality improvement
- study protocol
- pain management
- cardiovascular events
- randomized controlled trial
- risk factors
- type diabetes
- intensive care unit
- respiratory failure
- squamous cell carcinoma
- phase ii study
- radiation therapy
- extracorporeal membrane oxygenation
- combination therapy
- rectal cancer
- double blind
- acute respiratory distress syndrome
- replacement therapy
- smoking cessation